- |||||||||| cisplatin / Generic Mfg., Lipoplatin (cisplatin liposomal) / Regulon
Journal: Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy. (Pubmed Central) - Nov 21, 2019
We demonstrate that the vascular changes induced by RAPTA-T are related, in part, to the inhibition of poly-(ADP-ribose) polymerase 1 (PARP-1) which is associated to tumor vascular stabilization. These findings suggest novel therapeutic implications for RAPTA-T to create conditions for superior drug uptake and efficacy of approved cytotoxic anti-cancer drugs in malignant pleural mesothelioma and potentially other chemoresistant tumors.
- |||||||||| Lipoplatin (cisplatin liposomal) / Regulon
Journal: Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity. (Pubmed Central) - Oct 18, 2019
These findings suggest novel therapeutic implications for RAPTA-T to create conditions for superior drug uptake and efficacy of approved cytotoxic anti-cancer drugs in malignant pleural mesothelioma and potentially other chemoresistant tumors. LIPO showed less toxic effects in the HEI-OC1 cells compared to CDDP at anti-tumoral doses.
- |||||||||| Myocet (doxorubicin liposomal) / Teva, Sopherion, Lipoplatin (cisplatin liposomal) / Regulon
Journal: Data on cytotoxic pattern of cholesterol analogs for lung adenocarcinoma cells. (Pubmed Central) - Jul 25, 2019
We performed theoretical calculations of the biophysicochemical properties, and viability assays in a range of 5-100 μM in A549 cells of these Cho analogs. We used ChemSketch and ChemSpider to determine physical properties, and GraphPad Prism 8 software for the data analysis to determine the inhibitory concentrations at 50% (IC) of each compound.
- |||||||||| Lipoplatin (cisplatin liposomal) / Regulon, NN1213 / Novo Nordisk, Visudyne (verteporfin) / Novartis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PDT-lipo: Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies (clinicaltrials.gov) - Mar 20, 2019
P1, N=1, Terminated,
We used ChemSketch and ChemSpider to determine physical properties, and GraphPad Prism 8 software for the data analysis to determine the inhibitory concentrations at 50% (IC) of each compound. N=20 --> 1 | Trial completion date: Jun 2019 --> Aug 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Aug 2018; Drug supply issue
|
